UNSPSC 51392205: Detomidine

This classification denotes an alpha-adrenergic agonist with the molecular formula C12H14N2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7N8K34P2XH, chemically known as 4-(2,3-dimethylbenzyl)imidazole but generally known as detomidine, which bears US NIH Compound Identifier 56032. European Medicines Agency schedules Detomidine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07012MIG. The term DETOMIDINE is an International Non-Proprietary Name.

UNSPSC 51392205 Detomidine, a Commodity code, nominally describes a veterinary sedative; however, the recent state and local solicitation activity under this code reflects public health procurement of naloxone and drug deactivation systems rather than pharmaceutical compounds aligned with the code's stated definition. Seminole County, Florida's IFB60459723LAS sought 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to support community health initiatives. The mismatch between the code's nominal scope and actual procurement suggests either a cataloging error within the issuing jurisdiction's system or a deliberate use of an adjacent code to capture opioid-reversal and harm-reduction products. Vendors responding to such opportunities must meet standard state and local procurement requirements, including drug-free workplace certification, E-Verify compliance, workers' compensation and commercial general liability insurance, and a three-month probationary period.

Seminole County stands as the primary identified buyer under this code in recent activity. The IFB posted on June 30, 2026, with a response deadline of July 26, 2023 (an apparent date inconsistency in the source), required bidders to submit unit costs electronically through the county's e-Procurement Portal, include all shipping and delivery costs in their proposals, and comply with federal requirements when FEMA funding applies. The contract structure offers an initial two-year term with a one-year renewal option and is awarded on a fixed-fee basis. No explicit set-aside or disadvantaged-enterprise designations were noted in the procurement documentation.